Sequence Variations of Epstein-Barr Virus-Encoded Small Noncoding RNA and Latent Membrane Protein 1 in Hematologic Tumors in Northern China

• Published in: Intervirology Vol. 64; no. 2; pp. 69 - 80
• Main Authors: Wang, Hai-Yu, Sun, Lingling, Li, Ping, Liu, Wen, Zhang, Zhong-Guang, Luo, Bing
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.04.2021
• Subjects: Analysis; Antisense RNA; B cells; China - epidemiology; DNA sequencing; Epstein-Barr virus; Epstein-Barr Virus Infections - epidemiology; Ethylenediaminetetraacetic acid; Genetic aspects; Hematologic Neoplasms; Herpesvirus 4, Human - genetics; Humans; Leukemia; Membrane Proteins; Nucleotide sequencing; Research Article; RNA, Small Untranslated; RNA, Viral; Viral Matrix Proteins; China; Genotype; Epstein-Barr virus; Epstein-Barr virus-encoded small noncoding RNA; Hematologic tumors; Latent membrane protein 1; Polymorphism
• ISSN: 0300-5526; 1423-0100; 1423-0100
• DOI: 10.1159/000510398

Objective: To investigate the relationship between hematologic tumors and Epstein-Barr virus (EBV)-encoded small noncoding RNA (EBER) variations as well as latent membrane protein 1 (LMP1) variations. Methods: Patients with leukemia and myelodysplastic syndrome (MDS) were selected as subjects. Genotypes 1/2 and genotypes F/f were analyzed using the nested PCR technology, while EBER and LMP1 subtypes were analyzed by the nested PCR and DNA sequencing. Results: Type 1 was more dominant than type 2, found in 59 out of 82 (72%) leukemia and in 31 out of 35 (88.6%) MDS, while type F was more prevalent than type f in leukemia (83/85, 97.6%) and MDS (29/31, 93.5%) samples. The distribution of EBV genotypes 1/2 was not significantly different among leukemia, MDS, and healthy donor groups, neither was that of EBV genotypes F/f. EB-6m prototype was the dominant subtype of EBER in leukemia and MDS (73.2% [30/41] and 83.3% [10/12], respectively). The frequency of EB-6m was lower than that of healthy people (96.7%, 89/92), and the difference was significant (p < 0.05). China 1 subtype was the dominant subtype of LMP1 in leukemia and MDS (70% [28/40] and 90% [9/10], respectively), and there was no significant difference in the distribution of LMP1 subtypes among the 3 groups (p > 0.05). Conclusion: The distribution of EBV 1/2, F/f, EBER, and LMP1 subtypes in leukemia and MDS was similar to that in the background population in Northern China, which means that these subtypes may be rather region-restricted but not associated with leukemia and MDS pathogenesis.